Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Take the example I gave, the supplement. It shows prior clinical trial and other results that don't seem particularly relevant to the topic of the paper - brilacidin as an antiviral in cells. I don't think the brilacidin OM and UP trial results will be included in the final peer-reviewed paper.

I think overall what I was trying to say was that the paper repeated many aspects of prior PRs, blog posts, unrelated preclinical tests, and trial results that I doubt first author grad student Bakovic knows anything about. It's not just a paper reporting results of in vitro testing; it contained lots of the other stuff. While true, the discussion does read to me more like company PRs for brilacidin. Take your pick of items and wording

Selectivity Index (SI) for brilacidin of 426 (CC50=241µM/IC50=0.565µM)— strongly support
brilacidin’s treatment potential to achieve positive antiviral outcomes in humans.

Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control
both viral load and the corresponding inflammatory damage due to SARS-CoV-2,93 and mitigate
bacterial co-infections. Exhibiting three-in-one properties—antiviral, immuno/anti-inflammatory,
and antibacterial—brilacidin is being developed for the intravenous treatment of COVID-19 in
hospitalized patients and may be able to address different disease parameters within the one
therapeutic treatment.

Brilacidin has been successfully tested in 8 clinical trials across multiple indications providing
established safety and efficacy data on over 460 subjects.

This paper should definitely raise awareness of the promise of brilacidin. Pre-prints and original journal submissions surely are modified after peer review. It will be interesting to see how and where the paper turns up in print. I suspect some of the extraneous aspects of brilacidin won't make it into the final version. Peer reviewers almost always think of limitations of a study. Right now there is nothing except positive things in the discussion, so I'm expecting slightly less positivity.